Aristotle Atlantic Partners LLC Reduces Stock Position in Guardant Health, Inc. $GH

Aristotle Atlantic Partners LLC lessened its holdings in Guardant Health, Inc. (NASDAQ:GH) by 46.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 494,386 shares of the company’s stock after selling 429,348 shares during the quarter. Guardant Health makes up about 2.3% of Aristotle Atlantic Partners LLC’s holdings, making the stock its 11th largest position. Aristotle Atlantic Partners LLC owned 0.39% of Guardant Health worth $50,497,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. V Square Quantitative Management LLC purchased a new position in shares of Guardant Health during the fourth quarter worth about $27,000. Chesapeake Asset Management LLC purchased a new position in shares of Guardant Health during the fourth quarter worth about $28,000. Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of Guardant Health during the fourth quarter worth about $31,000. Elyxium Wealth LLC acquired a new stake in shares of Guardant Health during the fourth quarter worth about $35,000. Finally, Parallel Advisors LLC boosted its stake in shares of Guardant Health by 164.7% during the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after buying an additional 219 shares during the period. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Insider Buying and Selling at Guardant Health

In other Guardant Health news, insider John G. Saia sold 20,000 shares of the business’s stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $106.51, for a total value of $2,130,200.00. Following the transaction, the insider owned 45,950 shares in the company, valued at $4,894,134.50. The trade was a 30.33% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helmy Eltoukhy sold 100,000 shares of the business’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $126.30, for a total transaction of $12,630,000.00. Following the completion of the transaction, the chief executive officer owned 2,012,919 shares in the company, valued at $254,231,669.70. This represents a 4.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 449,006 shares of company stock worth $51,148,938. Corporate insiders own 5.60% of the company’s stock.

Guardant Health Stock Performance

GH stock opened at $129.11 on Thursday. The stock has a market capitalization of $17.12 billion, a P/E ratio of -38.09 and a beta of 1.61. Guardant Health, Inc. has a one year low of $40.35 and a one year high of $135.00. The company has a 50 day moving average price of $105.69 and a two-hundred day moving average price of $102.51.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on GH. Mizuho raised their price objective on shares of Guardant Health from $135.00 to $175.00 and gave the company an “outperform” rating in a research report on Monday, June 8th. The Goldman Sachs Group began coverage on shares of Guardant Health in a research report on Friday, June 5th. They issued a “buy” rating and a $165.00 price objective for the company. Leerink Partners raised their price objective on shares of Guardant Health from $170.00 to $180.00 and gave the company an “outperform” rating in a research report on Friday, February 20th. Barclays raised their price objective on shares of Guardant Health from $115.00 to $120.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. Finally, Royal Bank Of Canada began coverage on shares of Guardant Health in a research report on Thursday, June 11th. They issued an “outperform” rating and a $185.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Guardant Health has a consensus rating of “Moderate Buy” and a consensus price target of $141.95.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.